12 AI Updates Worth Taking a Look At

Page 5 of 11

7. Tempus AI, Inc. (NASDAQ:TEM)

Number of Hedge Fund Holders: 17

Tempus AI, Inc. (NASDAQ:TEM) is a healthcare technology, offering molecular diagnostics, clinical data insights, and trial-matching services for medical and research applications.

On February 21, Tempus AI partnered with Menarini Group and its subsidiary, Stemline Therapeutics, to improve metastatic breast cancer care using its AI-powered Next platform. The collaboration helps clinicians determine when ESR1 mutation testing is needed, following ASCO’s updated guidelines recommending liquid biopsy for better accuracy. Next will analyze patient data and alert physicians if testing is missing, ensuring timely treatment decisions. Tempus and Stemline executives highlighted the role of AI in improving precision medicine and optimizing patient care.

Page 5 of 11